Arcus Biosciences, Inc.
3928 Point Eden Way
Hayward
California
94545
United States
Tel: 510-694-6000
Website: http://www.arcusbio.com/
Email: jobs@arcusbio.com
About Arcus Biosciences, Inc.
Arcus was founded in 2015 with the vision of bringing together scientists, physicians, advisors, and other leaders with significant content-matter expertise to focus on developing highly-combinable, best-in-class cancer therapies. The complexity of the tumor microenvironment requires a deep scientific understanding to guide judicious combinations of therapeutic agents with potential synergistic activity and the ability to identify biomarkers to select patients most likely to achieve significant, durable responses to treatment. Since our inception, our focus has primarily been targeting well-understood biological pathways where the biology had not yet yielded high-quality medicines.
One of Arcus's early key competitive advantages was building a strong foundation of an industry-leading group of individuals who run our world-class discovery engine and development organization. We believe discovery is not a commodity and have invested in building a high-performing research organization. Through the efforts of our discovery and development teams, we were able to bring our first molecule in the clinic from concept to the clinical stage development in less than 21 months.
We have complemented our productive discovery organization with clinical and commercial leadership that has led multiple cancer immunotherapy programs from early-stage development though to successful global launches. As Arcus advances its product candidates through clinical studies, we work closely with the medical community, patients and caregivers to facilitate participation in our clinical trials enabling potential breakthrough medicines to reach patients faster.
Today, with four product candidates in the clinic across more than a dozen clinical studies in areas of high unmet need, we are well on our way to becoming a fully integrated biopharmaceutical company creating best-in-class cancer therapies.
Stock Symbol: RCUS
Stock Exchange: NYSE
140 articles with Arcus Biosciences, Inc.
-
Arcus Biosciences Announces New Employment Inducement Grants - Jan 25, 2022
1/25/2022
Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted six new employees options to purchase a total of 38,850 shares of the Company’s common stock at an exercise price per share of $31.75, which was the closing price on January 24, 2022, and restricted stock units to acquire a total of 925 shares of the Company’s common stock.
-
Arcus Biosciences Announces New Employment Inducement Grants - Jan 11, 2022
1/11/2022
Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted two new employees options to purchase a total of 41,800 shares of the Company’s common stock at an exercise price per share of $37.56, which was the closing price on January 10, 2022.
-
Arcus Biosciences Provides Update on Clinical Programs, Including Key 2022 Milestones
1/10/2022
Arcus Biosciences, Inc. today provided updates on clinical programs and key milestones anticipated in 2022.
-
Arcus Biosciences Announces New Employment Inducement Grants - Dec 24, 2021
12/24/2021
Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 23,400 shares of the Company’s common stock at an exercise price per share of $44.59, which was the closing price on December 23, 2021.
-
Gilead and Arcus Biosciences Complete Closing of Option Exercise for Three Clinical-stage Programs and New Research Collaboration
12/21/2021
Gilead Sciences, Inc. and Arcus Biosciences, Inc. announced the closing of Gilead’s option exercises to three programs in Arcus’ clinical-stage portfolio and a new research collaboration between the two companies.
-
Arcus Biosciences Announces New Employment Inducement Grants - Dec 09, 2021
12/9/2021
Arcus Biosciences, Inc., an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, announced that the Compensation Committee of the Company’s Board of Directors granted eight new employees options to purchase a total of 83,400 shares of the Company’s common stock at an exercise price per share of $44.17, which was the closing price on December 8, 2021.
-
Taiho Pharmaceutical Exercises Option for an Exclusive License to Arcus Biosciences’ Anti-TIGIT Program in Japan and Certain Territories in Asia
11/30/2021
Arcus Biosciences, Inc. and Taiho Pharmaceutical Co., Ltd. announced that Taiho exercised its option for anti-TIGIT antibodies domvanalimab and AB308 from Arcus Biosciences, in Japan and certain other territories in Asia.
-
Arcus Biosciences Announces New Employment Inducement Grants - Nov 24, 2021
11/24/2021
Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted ten new employees options to purchase a total of 76,000 shares of the Company’s common stock at an exercise price per share of $48.47, which was the closing price on November 23, 2021.
-
Arcus Biosciences to Participate in the Upcoming Evercore ISI HealthCONx 2021 Conference
11/22/2021
Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that management will participate in a fireside chat at the upcoming Evercore ISI HealthCONx 2021 Conference.
-
“I hope to thread the needle between pricing responsibly and achieving profitability," Jarrett said.
-
Gilead Exercises Options to Three Arcus Biosciences Clinical-stage Programs and Adds Research Collaboration
11/18/2021
Gilead Sciences, Inc. and Arcus Biosciences, Inc. announced that Gilead has exercised its options to three programs in Arcus’s clinical-stage portfolio, including both anti-TIGIT molecules, domvanalimab and AB308, as well as etrumadenant and quemliclustat.
-
Gilead Sciences announced it exercised its options to three of Arcus Biosciences’ programs. Two are anti-TIGIT molecules, domvanalimab and AB308, and the other is etrumadenant and quemliclustat.
-
Arcus Biosciences Announces New Employment Inducement Grants - Nov 09, 2021
11/9/2021
Arcus Biosciences, Inc., an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, announced that the Compensation Committee of the Company’s Board of Directors granted one new employee options to purchase a total of 28,000 shares of the Company’s common stock at an exercise price per share of $34.74, which was the closing price on November 8, 2021.
-
Arcus Biosciences Reports Third Quarter 2021 Financial Results and Provides an Update on our anti-TIGIT Domvanalimab
11/8/2021
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the third quarter ended September 30, 2021 and provided an update on the ARC-7 study of domvanalimab.
-
Arcus Biosciences to Report Third Quarter 2021 Financial Results & Recent Corporate Highlights
11/2/2021
Arcus Biosciences, Inc., a clinical-stage, global biopharmaceutical company focused on developing differentiated molecule and combination medicines for people with cancer, announced that the company will report its financial results and a corporate update for the third quarter ended September 30, 2021 after the market closes on Monday, November 8, 2021.
-
Arcus Biosciences Announces New Employment Inducement Grants - Oct 26, 2021
10/26/2021
Arcus Biosciences, Inc., an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, announced that the Compensation Committee of the Company’s Board of Directors granted six new employees options to purchase a total of 48,800 shares of the Company’s common stock at an exercise price per share of $34.38, which was the closing price on October 25, 2021.
-
This year – 2021 – will be a transformational year, Rosen predicted, citing three important milestones.
-
Arcus Biosciences Announces New Employment Inducement Grants - Oct 11, 2021
10/11/2021
Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted eight new employees options to purchase a total of 66,400 shares of the Company’s common stock at an exercise price per share of $31.48, which was the closing price on October 8, 2021.
-
Arcus Biosciences Announces New Employment Inducement Grants - Sep 27, 2021
9/27/2021
Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted eight new employees options to purchase a total of 58,200 shares of the Company’s common stock at an exercise price per share of $36.99, which was the closing price on September 23, 2021.
-
Arcus Biosciences Announces New Employment Inducement Grants - Sep 09, 2021
9/9/2021
Arcus Biosciences, Inc., an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, announced that the Compensation Committee of the Company’s Board of Directors granted five new employees options to purchase a total of 44,200 shares of the Company’s common stock at an exercise price per share of $34.31, which was the closing price on September 8, 2021.